To: 5.1.2e 5.1.2e @rivm.nl

From: 5.1.2e 5.1.2e Sent: Tue 1/21/2020 9:03:26 AM Subject: Re: WG: Corona EQA

Received: Tue 1/21/2020 9:03:46 AM

Yes, PCR testing of serum

I had 5.1.2e on the phone yesterday, he wants to talk to me again this morning after the discussion he had yesterday evening with ECRAID/PREPARE participants. do you know what is it about?

5.1.2e

Le 21/01/2020 à 09:43, 5.1.2e 5.1.2e a écrit :

Hi,

Ok. Is important to be in the loop to know where we are at.

Just to be clear: we decided on molecular EQA. Serology plays no role in coronavirus diagnostics. It might in epi studies but that is not the goal of this EQA. So 5.1.2e is only refering to molecular EQA?

Subject: Re: WG: Corona EQA

5.1.2e

The key point is to consolidate the EQA proposal to be made to WHO in order to be able to make a quote for both the supply of reagents and the administration of the EQA. I am working on that and I will discuss with how the administrative part will operate at RIVM. I still don't know the number of recipient labs identified by WHO branch offices.

I will keep you posted.

5.1.2e

Le 21/01/2020 à 09:30, 5.1.2e , 5.12e a écrit :

Dear 5.1.2e

I am re-sending yesterday's email with 5.1.2e in cc 5.1.2e please see below) so we can speed up things – I assume she is organizing the EQA read-out and communication via EVD-Labnet/WP5, right?

Best, 5.1.2e

__

nstitute of Virology

Charité - Universitätsmedizin Berlin



Hi 5.1.2e

I have just discussed the Corona PCR EQA with 5.1.2e We both agree with this highly relevant initiative. 5.1.2e lab is readily able to produce sufficient amounts of the 3 endemic human coronaviruses NL63, OC43 and 229E (that circulate worldwide and cause mostly common colds, all BSL-2), as well as SARS-CoV (the closest relative of the new Corona, BSL-3). By Mid-February, the new Wuhan Corona should be available from infectious clones.

I suggest to add the armored RNA that 5.1.2e is currently preparing, because they cover the target regions of the assays developed by Christian's lab. By joining the armored RNA and full virus we can be sure to have material that also allows to control for purification of nucleic acids.

Coronavirus inactivation protocols are readily established for all these viruses. Viruses will be quantified as absolute copy numbers and prepared in different concentrations and clinically relevant matrices, such as, but not limited to, materials from the upper and lower respiratory tract.

To facilitate shipment and avoid sending BSL-3 virus around, we will acquire an adequate lyophilizer of usage in our BSL-3 (about 5.1.1c. To ensure safety, we will reconstitute several vials and passage 3x to ensue lack of viral growth.

We roughly estimate another 511c for consumables and manpower, aiming at producing enough for an estimated 120 recipient labs. If we have to pay shipment on our end, I suggest to add at least another 511c (that would be about 5.1.1c mean per shipment). In sum, we should be able to fulfill all that is needed for 160K total.

Dear^{5,1,2e}

I forgot to highlight that we are uniquely suited for this EQA, because we are the lab that conducted the SARS EQA in 2004, including several labs that are also involved in the current outbreak:

Drosten C, Doerr HW, Lim W, Stöhr K, Niedrig M. SARS molecular detection external quality assurance. Emerg Infect Dis. 2004 Dec;10(12):2200-3.

And the single EQA dedicated to Brazilian labs during the Zika outbreak, highlighting the outreach of the actions we can assure in resource-limited settings:

Fischer C, Pedroso C, Mendrone A Jr, Bispo de Filippis AM, Vallinoto ACR, Ribeiro BM, Durigon EL, Marques ETA Jr, Campos GS, Viana IFT, Levi JE, Scarpelli LC, Nogueira ML, Bastos MS, Souza NCS, Khouri R, Lira S, Komninakis SV, Baronti C, Charrel RN, Kümmerer BM, Drosten C, Brites C, de Lamballerie X, Niedrig M, Netto EM, Drexler JF. External Quality Assessment for Zika Virus Molecular Diagnostic Testing, Brazil. Emerg Infect Dis. 2018 May; 24(5).

In case you want to incorporate this into the communication with WHO/ECDC.

Let us know your thoughts.

Best, 5.1.2e

--

5.1.2e

Charité - Universitätsmedizin Berlin

Charitéplatz 1, CCM/Rahel-Hirsch-Weg 3, 10117 Berlin, Germany

Tel. +49 5.1.2e Fax +49 5.1.2e e-mail: 5.1.2e @charite.de 5.1.2e

--

5.1.2e

www.european-virus-archive.com

Unite des Virus Emergents (UVE)

Aix-Marseille Universite-IRD 190-INSERM 1207-IRBA

IHU Infection, 19-21 Bd Jean Moulin, 13005 MARSEILLE, France



tel assist: 0033 5.1.2e

mob: 0033

fax: 0033

5.1.2e

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability

--

5.1.2e 5.1.2e

www.european-virus-archive.com

Unite des Virus Emergents (UVE)

Aix-Marseille Universite-IRD 190-INSERM 1207-IRBA

IHU Infection, 19-21 Bd Jean Moulin, 13005 MARSEILLE, France



tel assist: 0033 5

mob: 0033 (0) fax: 0033 (0)

5.1.2